Navigation Links
Nutra Pharma CEO Interviewed by Wall Street Reporter
Date:10/28/2011

CORAL SPRINGS, Fla., Oct. 28, 2011 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV/AIDS), Adrenomyeloneuropathy (AMN) and Pain, announced today that its Chief Executive Officer, Rik J. Deitsch, was interviewed by The Wall Street Reporter Senior Analyst Juan Costello. The interview provides an overview of the Company, its technology and an update on the Company's recent achievements. In addition, it provides a brief outlook of how Nutra Pharma views its business opportunities in the coming months.

"This interview has allowed us to provide some additional information on our two most recent press releases," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Recently, we announced the issuance of our newest patent that protects our drug technology for the treatment of Multiple Sclerosis. Additionally, we reported expanded international reach for our Nyloxin products through our new Distributor in Panama. The Company is now endeavoring to make it clear to the public that we have definitive short-term goals with the distribution of our drugs for the treatment of chronic pain; as well as long-term goals with our deep, drug discovery pipeline," he explained.

The interview is available on the Wall Street Reporter website under the "CEO Interviews" section and can be accessed directly via the link: http://tinyurl.com/NutraCEO

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The interview on The Wall Street Reporter should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
2. Nutrastar International Inc. Announces Record Second Quarter 2010 Results
3. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
4. 2nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More
5. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
6. WellGen Recognized as Nutraceutical “Innovator” by Global Business Insights
7. Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications
8. Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health
9. Reuters Highlights NutraPharma Financial Giant Predicts NutraPharma (OTCBB: NPHC) Shares Likely to Outperform the Market
10. Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
11. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2016. The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
(Date:5/23/2016)... LONDON , May 23, 2016 - ... by 40% - Frontage Implement a Single Platform to ... Compliance and Traceability Within the Bioanalytical lab Frontage Laboratories, ... the United States and China , ... its laboratory facilities. In addition to serving as the global electronic ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... 2016 , ... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma ., ... over 100 of their own patients with the VetStem Cell Therapy. Each of these ... for their patients. , The veterinarians are Dr Ross Rich former owner of ...
Breaking Biology Technology:
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® ... and enrollment solutions, today announced the addition of ... Altus multi-factor authentication platform. New contextual ... managers to step-up security where it,s needed most ... Washington, DC . --> ...
(Date:3/3/2016)... 2016  FlexTech, a SEMI Strategic Association Partner, awarded ... & Development, Leadership in Education, and, in a category ... th year of the FLEXI Awards and the ... from past years . Judging was done on ... of criteria, by a panel of non-affiliated, independent, industry ...
Breaking Biology News(10 mins):